The Mankind Pharma Limited (NSE:MANKIND) Full-Year Results Are Out And Analysts Have Published New Forecasts

Last week, you might have seen that Mankind Pharma Limited (NSE:MANKIND) released its full-year result to the market. The early response was not positive, with shares down 5.5% to ₹2,432 in the past week. The result was positive overall - although revenues of ₹122b were in line with what the analysts predicted, Mankind Pharma surprised by delivering a statutory profit of ₹49.20 per share, modestly greater than expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've discovered 1 warning sign about Mankind Pharma. View them for free.

Taking into account the latest results, the current consensus from Mankind Pharma's 16 analysts is for revenues of ₹148.3b in 2026. This would reflect a substantial 21% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to increase 5.2% to ₹50.64. In the lead-up to this report, the analysts had been modelling revenues of ₹150.0b and earnings per share (EPS) of ₹55.36 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

Check out our latest analysis for Mankind Pharma

The consensus price target held steady at ₹2,712, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Mankind Pharma at ₹3,300 per share, while the most bearish prices it at ₹2,150. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Mankind Pharma's rate of growth is expected to accelerate meaningfully, with the forecast 21% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 14% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Mankind Pharma to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹2,712, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Mankind Pharma analysts - going out to 2028, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Mankind Pharma that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.